The Portuguese Multi-Society Consensus (45) was the first to systematically standardize the clinical use of NT-proBNP in patients with DM, emphasizing routine testing in people over 50 years of age, initiating screening in younger patients based on risk factors, and recommending individualized adjustment of thresholds to provide a practical framework for the early identification of cardiac lesions and the development of therapeutic regimens. Here, NPPB is linked to diabetes mellitus.